PTC Therapeutics (NASDAQ:PTCT) Posts Earnings Results

PTC Therapeutics (NASDAQ:PTCT) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76), FiscalAI reports. The business had revenue of $357.81 million during the quarter, compared to the consensus estimate of $306.43 million. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 earnings per share.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT traded up $1.44 during midday trading on Thursday, reaching $64.46. The company’s stock had a trading volume of 1,524,172 shares, compared to its average volume of 996,871. PTC Therapeutics has a fifty-two week low of $58.80 and a fifty-two week high of $90.87. The company has a market capitalization of $5.38 billion, a P/E ratio of -111.14, a P/E/G ratio of 1.90 and a beta of 0.49. The business’s fifty day simple moving average is $65.57 and its 200-day simple moving average is $70.87.

Insider Activity at PTC Therapeutics

In other news, Director Michael Schmertzler sold 12,500 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $72.94, for a total transaction of $911,750.00. Following the sale, the director directly owned 1,349,094 shares of the company’s stock, valued at $98,402,916.36. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 2,813 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.57, for a total value of $204,139.41. Following the completion of the transaction, the vice president owned 105,272 shares in the company, valued at $7,639,589.04. The trade was a 2.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 77,370 shares of company stock valued at $5,322,261. Insiders own 5.30% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PTCT. Royal Bank Of Canada lowered their target price on shares of PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, October 7th. Weiss Ratings upgraded shares of PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Zacks Research downgraded shares of PTC Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. UBS Group assumed coverage on shares of PTC Therapeutics in a research report on Thursday, October 15th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Barclays boosted their price target on shares of PTC Therapeutics from $120.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.93.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.